La Jolla Pharmaceutical CO LJPC
We take great care to ensure that the data presented and summarized in this overview for LA JOLLA PHARMACEUTICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LJPC
Top Purchases
Top Sells
About LJPC
Insider Transactions at LJPC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 22
2022
|
David A Ramsay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
100,000
-100.0%
|
$600,000
$6.23 P/Share
|
|
Aug 22
2022
|
Tang Kevin C Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
19,215,868
-100.0%
|
$115,295,208
$6.23 P/Share
|
|
Aug 22
2022
|
Laura L. Johnson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
500
-100.0%
|
$3,000
$6.23 P/Share
|
|
Aug 22
2022
|
Craig A Johnson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,000
-100.0%
|
$72,000
$6.23 P/Share
|
|
Aug 22
2022
|
Michael S Hearne Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
9,607,934
-100.0%
|
$57,647,604
$6.23 P/Share
|
|
Aug 22
2022
|
Michael S Hearne Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,186
-100.0%
|
$61,116
$6.23 P/Share
|
|
Aug 22
2022
|
Larry G. Edwards Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,969
-100.0%
|
$71,814
$6.23 P/Share
|
|
Jul 08
2022
|
Craig A Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$36,000
$3.93 P/Share
|
|
Jun 30
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
236
+2.26%
|
$472
$2.71 P/Share
|
|
Jun 15
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
236
+2.32%
|
$472
$2.72 P/Share
|
|
May 31
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
189
+1.91%
|
$567
$3.41 P/Share
|
|
May 13
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
188
+1.94%
|
$564
$3.41 P/Share
|
|
Apr 29
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185
+1.94%
|
$555
$3.47 P/Share
|
|
Apr 14
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
173
+1.86%
|
$519
$3.71 P/Share
|
|
Apr 14
2022
|
Larry G. Edwards Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
296
+2.41%
|
$888
$3.71 P/Share
|
|
Mar 31
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
177
+1.93%
|
$531
$3.63 P/Share
|
|
Mar 31
2022
|
Larry G. Edwards Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
334
+2.78%
|
$1,002
$3.63 P/Share
|
|
Mar 15
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
190
+2.11%
|
$570
$3.37 P/Share
|
|
Mar 15
2022
|
Larry G. Edwards Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
361
+3.09%
|
$1,083
$3.37 P/Share
|
|
Feb 28
2022
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185
+2.1%
|
$555
$3.48 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders